Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in the first half of 2024.
Similar Posts
Tata Technologies IPO emerges as a strong investment opportunity
Post Content Post Views: 99
Gold prices rally before Fed minutes, copper rises on tighter supplies
Post Content Post Views: 124
Alchip Technologies launches advanced Automotive ASIC platform
Post Content Post Views: 121
US stocks mixed in subdued trading; Cyber Monday sales in focus
Post Content Post Views: 105
Gold prices retreat as U.S. dollar strengthens and yields rise
Post Content Post Views: 102
TDCX Non-GAAP EPS of $0.16, revenue of $119.8M
Post Content Post Views: 112